The 2025 American Medical Association (AMA) House of Delegates (HOD) Annual Meeting, held in Chicago from June 6-11, was a key platform for ASCO's delegation to engage in robust discussions and ...

After a fast-paced 2025 legislative session, in which all 50 states and Washington, D.C., convened, most legislatures have adjourned for the year. While several states entered the session with ...

On July 14, 2025, the Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician Fee Schedule (PFS) proposed rule for Calendar Year (CY) 2026, which includes changes related to ...

On June 27, 2025, the Centers for Medicare & Medicaid Services (CMS) announced a new Innovation Center payment and service delivery model aimed at reducing fraud, waste, and abuse in the Medicare ...

The budget reconciliation bill, known as the One Big Beautiful Bill (OBBB), a broad spending and tax bill that includes significant health care policies, was signed into law by President Trump on July ...

America’s Health Insurance Plans (AHIP)—a trade group representing the U.S. health insurance industry—announced a commitment from participating plansto improve prior authorization processes. The ...

A REMS letter for health care providershas been released to address the potential risk of severe hypocalcemia in patients with advanced chronic kidney disease following Jubbonti administration. More ...

This paper integrates stakeholder input and identifies potential components for the forthcoming Cures 2.1 legislation. It also builds on more than 300 stakeholder responses and aims to accelerate the ...

As AI use has grown, payers are regularly implementing their own algorithms to deny prior authorization requests. Many of these AI algorithms are proprietary, and there is no clear guidance on if or ...

CHICAGO — Results from the international phase 3 AMPLITUDE clinical trial found that adding niraparib to abiraterone acetate (AKEEGA™) plus prednisone (AAP) can help slow cancer growth for people with ...

CHICAGO — Results from the phase 3 DESTINY-Breast09 clinical trial found that the combination of trastuzumab deruxtecan (Enhertu®) with pertuzumab (Perjeta®) can delay cancer growth for longer than ...

“This is the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer to demonstrate that post-treatment exercise is both achievable and effective in improving ...